Skip to main content
Fig. 3 | Breast Cancer Research

Fig. 3

From: Local and distant tumor dormancy during early stage breast cancer are associated with the predominance of infiltrating T effector subsets

Fig. 3

FVBN202 transgenic mice bearing early stage primary breast cancer show distant tumor dormancy regardless of cancer therapies. Female FVBN202 transgenic mice (8–10 weeks old) were challenged with neu-overexpressing MMC in the mammary region (3 × 106 cells/mouse) or did not receive any tumor (naïve). Three days after challenge, tumor-bearing animals were split into three groups: one group received no treatment (Ctrl); second group received nine daily doses of FAC chemotherapy (10 mg/kg 5-FU + 3 mg/kg Adriamycin + 10 mg/kg Cyclophosphamide, i.p.) without immunotherapy (FAC) or followed by AIT and anti-PD-1 antibody therapy (FAC/AIT). Immunotherapy was started 1 week after the completion of FAC by a single i.v. injection of tumor-reactive immune cells (70 million cells/mouse) followed by five doses of anti-PD-1 antibody (100 mg/kg, every 3 days, i.p.). Animals were sacrificed 5 weeks after tumor challenge. Neu+ dormant tumor cells in the lungs (a) or in the liver (e) were detected on FVS negative (FVS−) viable cells (%total neu+ cells). Ki67 expression is shown on gated FVS− neu+ viable cells in the lungs (b) or in the liver (f). Gated FVS−CD3+ cells were analyzed for CD4+ or CD8+ T cells in the lungs (c, d) or in the liver (g, h). Gated FVS−CD3+CD4+ or CD8+ T cells were analyzed for T effector cells (Te, CD44+CD62L−), T effector/memory cells (Tem, CD44+CD62Llow), T central/memory cells (Tcm, CD44+CD62Lhigh), or T naïve cells (Tn, CD4−CD62L+) in the lungs (c, d) or in the liver (g, h)

Back to article page